The European Medicines Agency published its latest recommendations on PRIME scheme SME eligibility in early August 2026, covering the CHMP meeting of 20–23 July. Seven products were reviewed. Two advanced-therapy gene therapies received PRIME designation — both from “Other” (non-SME) applicants. Five were denied, including all three applications from small and medium-sized enterprises.

One month’s data is a snapshot. Placed alongside the rest of 2026 so far, a more nuanced picture emerges. SMEs did secure two PRIME designations earlier in the year (April). Yet from the January, June and July meetings combined, eight SME applications were reviewed and none were granted, while non-SME applicants achieved four successes out of nine in the same three meetings. The long-term gap in success rates remains clear.

The July Decisions in Detail

The two products that cleared the bar in July are both adeno-associated viral vector gene therapies — one targeting AIPL1-associated inherited retinal dystrophy, the other delivering GDNF for Parkinson’s disease. Both were supported by non-clinical plus exploratory clinical data, a package also submitted by every denied applicant. Data maturity alone was not the differentiator.

The five denials included three ATMPs or chemical entities from SMEs targeting primary hyperoxaluria type 1, non-small cell lung cancer, and SSTR2-positive gastroenteropancreatic neuroendocrine tumours. Two further denials came from non-SME sponsors in Huntington’s disease and vanishing white matter disease. All carried the same data category on paper. The CHMP reached different conclusions about the strength of the clinical signal and the degree of unmet need each product could credibly address at this stage.

The Cumulative Picture and 2026 Context

EMA’s cumulative statistics through 23 July 2026 show the longer-term differential. Since PRIME launched in March 2016:

• SMEs: 335 applications, 75 grants (22.4 % success rate)
• “Other” applicants: 275 applications, 96 grants (34.9 %)
• Academic sponsors: 9 applications, 3 grants

The absolute gap of roughly 12.5 percentage points has been stable for years.

Within 2026 specifically, April produced two SME grants (Zertomibgene cazparvovec for MYBPC3-related hypertrophic cardiomyopathy and an AAV9-PKP2 vector for arrhythmogenic right ventricular cardiomyopathy). Those successes demonstrate that SMEs can still meet the bar for PRIME scheme SME eligibility. However, the January meeting recorded two SME denials, June recorded three, and July added another three — eight consecutive SME applications without a grant across those three meetings. Non-SME applications in the same three meetings totalled nine, of which four succeeded. The recent streak therefore warrants attention even if it does not represent a complete year-to-date shutout.

Why the Differential Persists

Several factors likely contribute. The evidentiary threshold for PRIME is high and implicitly comparative: the applicant must show potential to address an unmet need to a degree that justifies enhanced regulatory support. Sponsors with dedicated regulatory teams and prior EMA experience may present that narrative more effectively.

Therapeutic area also matters. Oncology, the single largest category (approximately 164 cumulative applications), continues to show a low grant rate because demonstrating a major therapeutic advantage over a rapidly evolving standard of care is difficult at the exploratory stage. Two of July’s three SME denials were in oncology.

The Early Entry PRIME route, intended to lower the barrier for SMEs and academic sponsors by allowing applications on compelling non-clinical data plus first-in-human tolerability, remains available. Experience to date suggests that entry is one thing; successful designation is another.

Practical Implications for Smaller Developers

PRIME remains one of Europe’s most important early-access regulatory tools. With hundreds of applications received and roughly 170–180 designations granted since 2016, it has accelerated development for medicines addressing genuine unmet need. The two July grants — for a severe inherited retinal dystrophy and Parkinson’s disease — illustrate the kind of high-impact therapies the scheme was designed to support.

For SMEs the message is that eligibility turns on more than a promising molecule and early clinical data. It requires a regulatory narrative that convincingly links the data to a major therapeutic advantage, presented with a level of sophistication that many smaller companies still build in-house or via specialist partners.

Three practical considerations:

• Invest early in regulatory strategy. Engage the EMA SME office, request scientific advice, and consider parallel HTA scientific advice under the EU HTA Regulation. These steps help shape a development programme that anticipates the questions rapporteurs will ask.
• Time the application carefully. The “non-clinical plus clinical exploratory” label covers a wide spectrum of data maturity. Compelling proof-of-concept signals, rather than safety and tolerability alone, appear increasingly necessary even via the Early Entry route.
• Assess the therapeutic landscape honestly. In crowded fields such as NSCLC the burden of demonstrating a major advantage is especially high. Developers should judge whether their differentiation is strong enough at the current evidence stage or whether waiting for more mature data would improve the odds.

Looking Ahead

The 2026 data do not show that PRIME is closed to SMEs — April’s two grants prove otherwise — but they do confirm that the success-rate gap between large and small sponsors is real and that recent months have been particularly difficult for SME applicants. EMA’s expanded development-support tools (regulatory roadmaps, submission-readiness meetings and related measures) are steps in the right direction; their effect on SME outcomes will need continued monitoring.

As the revised EU pharmaceutical legislation and the joint clinical assessment framework under the HTA Regulation mature, the regulatory and access landscape will grow more complex. SMEs that build integrated regulatory–HTA capabilities now will be better placed for PRIME and for the broader pathway that follows. Continued European collaboration among HTA and regulatory agencies will further shape these outcomes.

Frequently Asked Questions

What factors influence PRIME scheme SME eligibility decisions?

Decisions hinge on the strength of the clinical signal, the degree of unmet need, and how convincingly the data package demonstrates major therapeutic advantage. SMEs often face challenges in presenting this narrative with the same sophistication as larger sponsors.

How can SMEs improve their chances of securing PRIME designation?

Early investment in regulatory strategy, engagement with the EMA SME office, timely applications supported by compelling proof-of-concept data, and honest assessment of the competitive landscape all help strengthen an application.

Does the recent data mean PRIME is closed to small companies?

No. While SME success rates lag behind those of larger applicants and recent months have been challenging, April 2026 saw two SME grants, showing that eligible products from smaller developers can still succeed when the evidence package is robust.

Bibliography

European Medicines Agency. (2026). PRIME: priority medicines. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines (key figures and outcomes updated to the CHMP meeting of 20–23 July 2026).

European Medicines Agency. (2026, 10 August). Recommendations on eligibility to PRIME scheme – Adopted at the CHMP meeting of 20–23 July 2026 (EMA/164693/2026). https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-july-2026_en.pdf

European Medicines Agency. (2026, 7 May). Recommendations on eligibility to PRIME scheme – Adopted at the CHMP meeting of 20–23 April 2026 (EMA/93274/2026). https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-20-23-april-2026_en.pdf

European Medicines Agency. (2026, 7 July). Recommendations on eligibility to PRIME scheme – Adopted at the CHMP meeting of 22–25 June 2026 (EMA/145490/2026). https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-22-25-june-2026_en.pdf

European Medicines Agency. (2026, 4 February). Recommendations on eligibility to PRIME scheme – Adopted at the CHMP meeting of 26–29 January 2026 (EMA/18748/2026). https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-26-29-january-2026_en.pdf

European Medicines Agency. (2026). European Medicines Agency guidance for applicants seeking access to PRIME scheme (EMA/7872/2021, revised). https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-applicants-seeking-access-prime-scheme_en.pdf